Sanofi R&D expenditure 2025| ��ƽ��

Research and development expenditure of Sanofi from 2008 to 2025 (in million euros)

Characteristic	Expenditure in million euros
2025	7,842
2024*	7,394
2023	6,507
2022	6,706
2021	5,692
2020	5,530
2019	6,018
2018	5,894
2017	5,472
2016	5,172
2015	5,082
2014	4,667
2013	4,605
2012	4,922
2011	4,811
2010	4,556
2009	4,628
2008	4,575

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

February 2026

More information

Region

Worldwide, France

Survey time period

2008 to 2025

Supplementary notes

Figures for 2008-2022 were taken from previous annual financial reports.

*For 2024, the Consumer Healthcare segment (new name 'Opella') is already classified as a discontinued operation, and thus not included

Citation formats

In 2025, biopharmaceutical company Sanofi spent approximately 7.8 billion euros on research and development. Sanofi’s R&D expenditures have increased over most of the provided period, with exceptions being the years 2020 and 2023.

The French pharmaceutical giant

Sanofi Société Anonyme (or Sanofi S.A.), headquartered in Paris, France, is active in more than one hundred countries worldwide, with a global workforce of around 75 thousand people in 2025. The company generates most of its revenue from its biopharma segment, while over five billion euros were earned through the company’s consumer healthcare segment (only until 2023). Sanofi is also a global leader in vaccines. In 2024, some 2.6 billion euros were generated through influenza vaccines.

Clinical trials

A clinical trial or study is conducted to uncover whether a particular compound is efficient and safe to use for the treatment of people. It is a lengthy process that can take several years. Such trials are also necessary to get a vaccine or a drug approved for marketing purposes.